Section Arrow
Quote
TVRD.NASDAQ
- Tvardi Therapeutics Inc
Quotes are at least 15-min delayed:2026/05/27 04:40 EDT
Pre Market
Last
 3.31
-0.13 (-3.78%)
Bid
3.3
Ask
4.5
High 3.44 
Low 3.31 
Volume 13 
Regular Hours (Closed)
Last
 3.44
-0.13 (-3.64%)
Day High 
3.59 
Prev. Close
3.57 
1-M High
4.3399 
Volume 
55.69K 
Bid
3.3
Ask
4.5
Day Low
3.29 
Open
3.57 
1-M Low
2.995 
Market Cap 
33.49M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.86 
20-SMA 3.67 
50-SMA 3.43 
52-W High 43.65 
52-W Low 2.75 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.27/-3.02
Enterprise Value
33.58M
Balance Sheet
Book Value Per Share
1.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.14M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.4002+0.0903+29.14%-- 
Pre Market 0.398 -0.0022 -0.55%
SNGXSoligenix Inc.0.513+0.1229+31.50%-- 
Pre Market 1.0785 +0.5655 +110.23%
PHGEBiomX Inc.1.62+0.8035+98.41%-- 
Pre Market 1.38 -0.24 -14.81%
RXRXRecursion Pharmaceuticals2.97-0.04-1.33%-- 
Pre Market 2.975 +0.005 +0.17%
ARTLArtelo Biosciences Inc1.71+0.52+43.70%-- 
Pre Market 1.28 -0.43 -25.15%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.